| human | Q5 |
| P856 | official website | https://synapse.mskcc.org/synapse/people/1893 |
| P496 | ORCID iD | 0000-0002-3109-1692 |
| P1416 | affiliation | University of Virginia | Q213439 |
| P69 | educated at | University of Virginia | Q213439 |
| P108 | employer | Memorial Sloan Kettering Cancer Center | Q1808012 |
| P734 | family name | Robson | Q16882155 |
| Robson | Q16882155 | ||
| Robson | Q16882155 | ||
| P735 | given name | Mark | Q13610143 |
| Mark | Q13610143 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q57907630 | 453 THE ASSOCIATION OF GENITOURINARY CANCERS WITH BRCA CARRIER STATUS IN A CLINICALLY TESTED COHORT FROM A SINGLE INSTITUTION |
| Q56928435 | A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy |
| Q40495288 | A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer |
| Q24803679 | A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment |
| Q46533348 | A comparison of bilateral breast cancers in BRCA carriers |
| Q37197579 | A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q30951799 | A note on competing risks in survival data analysis |
| Q46518366 | A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer |
| Q37719595 | A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers |
| Q38811820 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale |
| Q56928428 | Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families |
| Q56928450 | Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens fromBRCA1 heterozygotes |
| Q40270974 | Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q53557259 | American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. |
| Q37672016 | American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility |
| Q37157589 | American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment |
| Q34632472 | An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions |
| Q33901361 | An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q28393099 | Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report |
| Q45159522 | Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series |
| Q34074436 | Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q34806183 | Assessment of SLX4 Mutations in Hereditary Breast Cancers |
| Q54996542 | Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families |
| Q56928424 | Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes |
| Q56928440 | Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q36854437 | BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma |
| Q47637460 | BRCA mutations and risk of prostate cancer in Ashkenazi Jews |
| Q44064681 | BRCA mutations in women with ductal carcinoma in situ |
| Q43459769 | BRCA-associated breast cancer in young women |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q38643830 | Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis |
| Q44462595 | Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis |
| Q57420847 | Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study |
| Q56928439 | Breast MRI for Women With Hereditary Cancer Risk |
| Q37006537 | Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort |
| Q46520947 | Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. |
| Q35928599 | Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations |
| Q38466484 | Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. |
| Q38107807 | Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer |
| Q56928430 | CHEK2, breast cancer, and the understanding of clinical utility |
| Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
| Q38180646 | Cancer genomics and inherited risk |
| Q101237548 | Cancer therapy shapes the fitness landscape of clonal hematopoiesis |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q96952513 | Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma |
| Q35039478 | Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. |
| Q36877519 | Clinical practice. Management of an inherited predisposition to breast cancer |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q30410984 | Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35846927 | Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women |
| Q44250031 | Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation? |
| Q47402328 | Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study |
| Q27928062 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 |
| Q51984090 | Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. |
| Q51775978 | Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. |
| Q56928441 | Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations |
| Q91388575 | Erratum: Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers |
| Q45103435 | Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers |
| Q56928445 | Estrogen Receptor-Beta Expression in Hereditary Breast Cancer |
| Q35118969 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q52560326 | Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. |
| Q35582709 | Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations |
| Q56928413 | Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy |
| Q37614573 | Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q24798279 | Frequency of CHEK2*1100delC in New York breast cancer cases and controls |
| Q36408445 | Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant |
| Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
| Q56928412 | Genetic Epidemiology of Breast Cancer |
| Q30696780 | Genetic Testing Awareness and Attitudes among Latinos: Exploring Shared Perceptions and Gender-Based Differences |
| Q33570452 | Genetic analysis of the early natural history of epithelial ovarian carcinoma |
| Q57907606 | Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant |
| Q34193988 | Genome-wide association studies of cancer |
| Q37785242 | Genome-wide association studies of cancer predisposition |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q37677557 | Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer |
| Q37019841 | Germline BRCA mutations denote a clinicopathologic subset of prostate cancer |
| Q47122725 | Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care |
| Q35546231 | Germline EGFR T790M mutation found in multiple members of a familial cohort |
| Q56928422 | Germline PALB2 mutation analysis in breast-pancreas cancer families |
| Q124151392 | Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer |
| Q112577396 | Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination |
| Q33817011 | Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. |
| Q34414768 | Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. |
| Q33699684 | Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates |
| Q56928447 | Hereditary breast cancer |
| Q73932929 | Hereditary breast cancer |
| Q35934068 | Hereditary ovarian cancer in Ashkenazi Jews |
| Q33289120 | Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis |
| Q91452763 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants |
| Q92716347 | Homologous recombination DNA repair defects in PALB2-associated breast cancers |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q37540235 | Identification of germline genetic mutations in patients with pancreatic cancer |
| Q28285540 | Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans |
| Q56928443 | Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers |
| Q56928433 | Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer |
| Q45003956 | Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers |
| Q37179254 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer |
| Q113757773 | Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer |
| Q37785233 | Inherited predisposition to cancer: introduction and overview |
| Q54996503 | Inherited predisposition to endometrial cancer: Moving beyond Lynch syndrome |
| Q37403013 | Inherited predisposition to gastrointestinal stromal tumor |
| Q37699263 | Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. |
| Q54581835 | Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. |
| Q56928434 | Is breast conservation a reasonable option for women with BRCA-associated breast cancer? |
| Q35204670 | MRI of occult breast carcinoma in a high-risk population. |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q51155217 | Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. |
| Q87968246 | Multigene panel testing: planning the next generation of research studies in clinical cancer genetics |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
| Q56928418 | NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement |
| Q34571689 | Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q39348799 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation |
| Q52841132 | Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. |
| Q56928437 | Oligogenic combinations associated with breast cancer risk in women under 53 years of age |
| Q64242044 | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer |
| Q54996355 | Oophorectomy for BRCA1 ER-negative disease—an open debate |
| Q52943903 | Oophorectomy in carriers of BRCA mutations. |
| Q34162534 | Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers |
| Q30080035 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial |
| Q52123195 | Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. |
| Q45140483 | Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q36158193 | Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q92846910 | Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial |
| Q46938331 | Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer |
| Q45050380 | Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer |
| Q47192462 | Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia |
| Q33669053 | Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q51023688 | Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q56928426 | Preface |
| Q37877648 | Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer |
| Q37129669 | Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. |
| Q37293360 | Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. |
| Q46295132 | Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. |
| Q56928446 | Prophylactic Mastectomy in Carriers ofBRCAMutations |
| Q95801322 | Prophylactic mastectomy in carriers of BRCA mutations |
| Q36627571 | Protecting the privacy of third-party information: recommendations for social and behavioral health researchers |
| Q94562441 | Protein-altering germline mutations implicate novel genes related to lung cancer development |
| Q51026427 | Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. |
| Q41768169 | Rare de novo germline copy-number variation in testicular cancer |
| Q56928442 | Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q36119158 | Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women |
| Q53539899 | Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. |
| Q57269829 | Response: Table 1 |
| Q39531185 | Revealing the incidentalome when targeting the tumor genome |
| Q56928436 | Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families |
| Q44832461 | Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer |
| Q34749278 | Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study |
| Q34129784 | Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation |
| Q56928415 | Risks to Relatives in Genomic Research: A Duty to Warn? |
| Q35967349 | Screening for germline EGFR T790M mutations through lung cancer genotyping |
| Q46254589 | Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia |
| Q44732177 | Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? |
| Q56928421 | Should the Presence of GermlineBRCA1/2Mutations Influence Treatment Selection in Breast Cancer? |
| Q34548726 | Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update |
| Q112778492 | Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion |
| Q28943260 | Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies |
| Q101061140 | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes |
| Q36714877 | TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression |
| Q34512590 | Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group |
| Q44199927 | Tamoxifen for primary breast cancer prevention in BRCA heterozygotes. |
| Q34858803 | The 6q22.33 locus and breast cancer susceptibility |
| Q57907556 | The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results |
| Q40414571 | The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds |
| Q100752677 | The genomic landscape of metastatic histologic special types of invasive breast cancer |
| Q46716138 | The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. |
| Q112778516 | Therapeutic Implications of Germline Testing in Patients With Advanced Cancers |
| Q36963440 | Treatment of hereditary breast cancer |
| Q33793932 | Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer |
| Q33912733 | What women with breast cancer discuss with clinicians about risk for their adolescent daughters |
| Q102328015 | Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial |
Search more.